Mark Litton
Chief Executive Officer bei ATHIRA PHARMA, INC.
Vermögen: 315 045 $ am 30.04.2024
Aktive Positionen von Mark Litton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ATHIRA PHARMA, INC. | Director/Board Member | - | - |
Chief Executive Officer | 16.06.2021 | - | |
President | 16.06.2021 | - | |
Chief Operating Officer | 11.07.2019 | 18.10.2021 | |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Director/Board Member | - | - |
Karriereverlauf von Mark Litton
Ehemalige bekannte Positionen von Mark Litton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Chief Operating Officer | 06.08.2018 | 16.04.2019 |
President | 06.08.2018 | 16.04.2019 | |
ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 01.01.2004 | 26.02.2010 |
Founder | 01.01.2004 | 01.08.2018 | |
Public Communications Contact | 01.01.2004 | - | |
Corporate Officer/Principal | 01.01.2004 | 26.02.2010 | |
Corporate Secretary | 01.01.2004 | 01.08.2018 | |
Treasurer | 26.02.2010 | 01.08.2018 | |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 01.01.1999 | 01.01.2004 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01.01.1997 | 01.01.1999 |
DNAX Research, Inc. | Corporate Officer/Principal | 01.01.1991 | 01.01.1994 |
Chiroscience Group Plc | Corporate Officer/Principal | 01.01.1999 | - |
Ausbildung von Mark Litton
Santa Clara University | Masters Business Admin |
University of California, Santa Cruz | Undergraduate Degree |
University of Stockholm | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Vereinigtes Königreich | 3 |
Schweden | 2 |
Operativ
Corporate Officer/Principal | 5 |
Director/Board Member | 3 |
Chief Operating Officer | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ATHIRA PHARMA, INC. | Health Technology |
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Chiroscience Group Plc | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
DNAX Research, Inc. | |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Health Technology |
- Börse
- Insiders
- Mark Litton
- Erfahrung